Table 1.
Patient demographic characteristics
| Before match | After match | |||||
|---|---|---|---|---|---|---|
| FEC | FDC | P‐value | FEC | FDC | P‐value | |
| N | 2673 | 946 | 878 | 878 | ||
| Male (%) | 1269 (47.5) | 482 (51.0) | .07 | 428 (48.7) | 453 (51.6) | .25 |
| Age (mean [sd]) | 58.05 (11.74) | 58.60 (11.48) | .21 | 58.01 (11.66) | 58.36 (11.48) | .53 |
| Type 2 diabetes mellitus (%) | 929 (34.8) | 481 (50.8) | <.001 | 405 (46.1) | 423 (48.2) | .42 |
| Chronic kidney disease (%) | 65 (2.4) | 17 (1.8) | .32 | 16 (1.8) | 14 (1.6) | .85 |
| Charlson comorbidity index (mean [sd]) | 0.66 (1.16) | 1.28 (1.30) | <.001 | 1.12 (1.42) | 1.15 (1.21) | .56 |
| Baseline concomitant medications | ||||||
| Antiplatelet agents (%) | 280 (10.5) | 189 (20.0) | <.001 | 151 (17.2) | 155 (17.7) | .85 |
| ACE inhibitors (%) | 408 (15.3) | 210 (22.2) | <.001 | 185 (21.1) | 188 (21.4) | .91 |
| ARBs (%) | 596 (22.3) | 453 (47.9) | <.001 | 404 (46.0) | 391 (44.5) | .57 |
| Beta‐blockers (%) | 646 (24.2) | 347 (36.7) | <.001 | 306 (34.9) | 304 (34.6) | .96 |
| Diuretics (%) | 334 (12.5) | 174 (18.4) | <.001 | 144 (16.4) | 152 (17.3) | .66 |
| Oral hypoglycemic agents (%) | 799 (29.9) | 433 (45.8) | <.001 | 364 (41.5) | 377 (42.9) | .56 |
| Insulin (%) | 147 (5.5) | 102 (10.8) | <.001 | 84 (9.6) | 82 (9.3) | .94 |
| Other anti‐HTN agents (%) | 65 (2.4) | 43 (4.5) | .002 | 34 (3.9) | 38 (4.3) | .72 |
Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin‐receptor blocker; FDC, fixed‐dose combination; FEC, free‐equivalent combination; HTN, hypertension.